Announcements Trials
Browse Landscape

Phase

Phase 4 5Phase 3 3Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 8Pain 7Cancer Pain 3Pancreatic Neoplasms 2Breast Neoplasms 2Breakthrough Pain 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thymoma 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stomach Neoplasms 1Standard Opioid Analgesic Treatment of Cancer-related Chronic Pain. 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Morphine 6nabiximols 4Oxycodone 3Fentanyl 3Methadone 2Hydromorphone 2Acetaminophen 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1resiniferatoxin 1naloxegol 1Tapentadol 1Sugars 1Standard of Care 1Lidocaine 1Inosine Monophosphate 1Donepezil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Cancer Pain × Fentanyl × Clear all
NCT00683995 2020-08-28

A Phase III Clinical Study of KW-2246

Kyowa Kirin Co., Ltd.

Phase 3 Completed
43 enrolled

Cancer Pain

NCT00684632 2020-08-28

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
51 enrolled

Cancer Pain

NCT00459277 2012-01-25

Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

Archimedes Development Ltd

Phase 3 Completed
73 enrolled

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡